Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.
Mafalda Oliveira, MD, PhD
Advertisement
Articles by Mafalda Oliveira, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
The OncFive: Top Oncology Articles for the Week of 7/12
5